UBS’s VanEck Biotech ETF BBH Stock Holding History

UBS’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$32K	Buy	+300	New	+$30.4K	﹤0.01%	7380

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

LFM

Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return

ECML

Eagle Capital Management (Louisiana) Mandeville, Louisiana $293M AUM 33.65% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

AHS

Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

UBS's BBH Position: Q3 2014 in Review

UBS increased its VanEck Biotech ETF (BBH) stake by 6.9% in Q3 2014, buying an estimated $1.18M and bringing the position to 179,332 shares worth $19M. The position accounts for 0.01% of the portfolio, ranked #987.

UBS first reported a position in BBH in Q2 2013 and has held it in 6 quarters since. 59 funds tracked by Wall St. Rank hold BBH as of Q3 2014.

UBS held 179,332 shares of VanEck Biotech ETF worth $19M as of Q3 2014.
UBS bought 11,632 VanEck Biotech ETF shares in Q3 2014, an estimated $1.18M.
VanEck Biotech ETF made up 0.01% of UBS's portfolio in Q3 2014, its #987 holding.
UBS first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 6 quarters since.
59 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.